Dreicer, Robert <br/><br/>
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2014 
 - 1335-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-13-2436  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Humans<br/>Imidazoles--pharmacology<br/>Male<br/>Middle Aged<br/>Naphthalenes--pharmacology<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Steroid 17-alpha-Hydroxylase--antagonists & inhibitors<br/>Treatment Outcome